Carsten Lønborg Madsen

Carsten Lønborg Madsen asked for confirmation on whether the API build-out for CapEx is on track, noting that the program seems longer and more expensive than previously expected. He also inquired about the immediate launch plans for the high-dose Wegovy (7.2mg) upon approval and the type of pen device it would be launched in.

Answer

Karsten Munk Knudsen (CFO, Novo Nordisk) confirmed that CapEx is trending downwards, with major API facilities expected online this year and more in coming years, indicating the program is broadly on track despite some project variations. Maziar Doustdar (CEO, Novo Nordisk) stated that Novo Nordisk is ready to launch the 7.2mg Wegovy immediately upon expected Q1 approval, emphasizing its comparable weight loss efficacy to tirzepatide and additional CV/kidney/liver benefits. It will launch in the same type of devices currently available.

Carsten Lønborg Madsen asked for confirmation on whether the API build-out program is on track, given the high CapEx levels, and if it's taking longer and costing more than initially expected. He also inquired about the immediate launch plans for the high-dose 7.2mg Wegovy upon approval and the type of pen device it would use.

Answer

CFO Karsten Munk Knudsen confirmed that CapEx is starting to decline, with a steeper slope expected in coming years as projects finalize. He stated that the API build-out is on track, with major new facilities expected online this year and more in subsequent years. CEO Maziar Doustdar confirmed that Novo Nordisk is ready to launch the 7.2mg Wegovy immediately upon expected approval this quarter, emphasizing its comparable weight loss efficacy to tirzepatide along with additional CV, kidney, and liver benefits, and will use the same type of pen devices currently available.